TMC launches new biotech partnership with Republic of Korea

international collaboration

The Texas Medical Center and KBIOHealth have launched the TMC Republic of Korea BioBridge. Photo via LinkedIn.

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.

From Your Site Articles
The Texas Medical Center has named its second cohort for its United Kingdom-focused health tech accelerator. Photo via TMC

16 digital health, medical device companies selected for UK, TMC accelerator

coming to Hou

For the second time, an accelerator backed by the United Kingdom and hosted by Texas Medical Center Innovation has named 16 companies to its new cohort.

In partnership with Innovate UK, TMC named the new cohort companies in an announcement this week. The companies are divided into two categories — digital health and medical device — and cover a wide range of specialties, from diagnostics and AI monitoring to non-surgical management and more.

The accelerator launched last year with its inaugural cohort with the mission of helping companies make their United States expansion by way of the TMC.

"The first cohort of startups in our accelerator program experienced TMC's capabilities in developing and advancing solutions through cross-collaboration with top minds in clinical care, commercialization and innovation," Devin Dunn, head of the Accelerator for Health Tech at TMC, says in a news release. "We are excited to continue our partnership with Innovate UK and welcome this second cohort to continue our efforts advancing life sciences technologies across the globe."

This year's program begins June 4 and will run through November. According to the TMC, last year's cohort had significant success tapping into the health tech ecosystem in Houston, including engaging with investors, setting up a go-to-market strategy, and making inaugural U.S.-based hires.

“Our Global Incubator Programme selects driven and ambitious innovators looking to scale their technologies globally," adds Jon Hazell, partnership manager for the North America and Global Incubator at Innovate UK. "We are excited for our second cohort of startups to join the programme, supported by the Texas Medical Center accelerator, where world-class mentors and programming will help our entrepreneurs understand and meet the requirements of different markets, and build the necessary partnerships, collaborations, and networks, facilitating their entry into global markets."

The selected medical device companies — and their technologies, as described by the TMC — include:

  • Cytecom – infectious diagnostic test, powered by cutting-edge optical electrophysiology, detects resistant bacteria in just 45 seconds, enabling doctors to prescribe targeted antibiotics in minutes instead of days
  • Heartfelt Technologies Ltd – the future of heart failure telemonitoring an automatic, AI supported, non-contact telemonitoring solution for heart failure patients
  • Neurovalens Ltd – creates wearable neurostimulaton devices that treat a range of conditions in an entirely non-invasive and drug-free way
  • Oxford Medical Products Limited – a proprietary hydrogel pill that acts as a non-surgical, non-pharmacological obesity treatment that will redefine the obesity treatment market
  • Phenutest – a rapid point-of-care diagnostic test for urinary tract infection, that confirms infection and appropriate antimicrobial to prescribe within 60 minutes
  • Plexaa – world's first fully wearable, sensor controlled, bra insert that can deliver safe supraphysiological preconditioning to the breast skin the night before surgery at home
  • SolasCure Limited – a wound Gel that acts as a single, effective and easy-to-use solution to overcome the challenges to transform chronic wound care
  • Trueinvivo Limited – a proprietary dosimetry (radiation measurement) system to ensure the precision and accuracy of cancer radiotherapy

The selected digital health companies — and their technologies, as described by the TMC — include:

  • Axon Diagnostics – offers a suite of solutions to support the needs of modern day diagnostic imaging services, supporting happier lives for clinicians and helping deliver better diagnostic care for all
  • Kheiron Medical Technologies – regarded as a world leader in the development of AI-enabled cancer diagnostics and monitoring
  • KiActiv – a technology-enabled digital health model for behaviour change and self-care that rethinks exercise and makes everyday movement an effective personalized medicine for better clinical outcomes
  • Memory Lane Games – turns memories into games, offering care providers a simple, fun dementia engagement app designed to trigger positive memories and improve socialisation with caregivers and people living with dementia
  • NeuroVirt Limited – combines immersive VR, AI and computer vision to gamify rehabilitation and quantify patient impairment and improvement
  • Newton’s Tree – enables healthcare providers to procure, integrate, and monitor third party AI products as part of routine care pathways through its enterprise AI platform
  • SERG Technologies – uses patented sensor technology and artificial intelligence to transform disease management into a continuous, data driven, and patient specific approach for people with Parkinson’s
  • Thymia – leverages speech, video, and behavioral analytics gathered via specially designed video games to diagnose conditions like depression, anxiety, and ADHD, alongside critical symptoms like fatigue, mood fluctuations, and memory issues, creating novel mental health biomarkers
The partnership between the U.K. and TMC began in 2018 as a biobridge between the two entities. TMC has expanded into new biobridges with other countries — most recently with The Netherlands — and also has a Danish accelerator that's also running its second cohort this summer.
The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

TMC names inaugural cohort for unique accelerator with UK

coming to HOU

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.
A new program established at TMC in partnership with Denmark will support the growth of three health tech companies. Photo courtesy of TMC

TMC launches co-hosted health tech accelerator with Denmark

biobridge support

Years ago, the Texas Medical Center established a biobridge to exchange technology and support with Denmark. Now, the two organizations are coming together to advance three health tech startups through a unique accelerator.

TMC and Denmark-based BioInnovation Institute announced today that three companies from BII will join a customized accelerator program that will guide them toward a United States go-to-market strategy. The program will be built off of the TMCi Health Tech Accelerator program.

“At TMC, we are elevating our ability to create curated go-to-market experiences for hand-selected companies that have a relationship with our partners at the BioInnovation Institute and that are seeking to prepare for of market expansion in the U.S.,” says Emily Reiser, associate director of TMC Innovation, in a news release. “We are excited about the opportunity to collaborate with BII and these founders.”

The three startups will head to Houston next week and incubate for six months, working with TMCi advisers and mentors on their individual challenges within commercialization and U.S. expansion. The three companies in the program are:

  • Aiomic, which is developing Aiomic360, an AI platform for postoperative complications. "With automated tracking and real-time risk assessment, Aiomic360 will function as a quality management tool for hospitals, a decision support tool for healthcare practitioners, and an individualized patient empowerment tool for surgical candidates," per the release.
  • Also tapping into AI, Orbit Health's solution, Neptune, is using motion data from smartwatches to track Parkinson’s motor state and treatment response passively. "Its continuous and objective insights enable regular treatment personalization that is needed throughout the course of the disease to optimize patient outcomes and improve quality of life," reads the release.
  • HEI Therapeutics is enabling at-home hypothyroidism management. "The innovative solution includes a patented finger stick blood test and digital patient empowerment tools and aims to significantly reduce the share of patients that is poorly regulated with medication," according to the release.

The TMC and the Ministry of Foreign Affairs of Denmark launched the Biobridge in 2019. BII is a nonprofit organization with a few resources — the Bio Studio, Venture Lab, and Venture House — that support life science startups with resources and even funding of up to €3 million per projects and €1.8 million per company.

“As we strengthen our offering to support visionary healthcare innovators to develop products and solutions to address clear unmet needs, our partnership with Texas Medical Center allows BII startups to gain exposure to US market and ready themselves for US market entry. We are thrilled about this collaboration with the Texas Medical Center which is one of the largest life science ecosystems in the world,” says Tony Cheng-fu Chang, principal at BioInnovation Institute. “Through the customized accelerator program, these three healthcare startups will acquire critical insight to create field-ready plans for bringing their products and solutions to the US market.”

Insight Surgery is opening its first international location, and the UK company chose Houston for it. Photo via 3dlifeprints.com

UK personalized surgery startup rebrands, expands to US by way of Houston

crossing the atlantic

An innovative health tech company headquartered in the United Kingdom has made its entrance into the United States — and Houston's Texas Medical Center is where it's setting up shop.

The company, newly renamed to Insight Surgery — neé 3D LifePrints — was originally established in 2011 by Paul Fotheringham as a social enterprise to create 3D printed prosthetics for amputees in Kenya. While the company still provides this care to developing countries, Fotheringham, who serves as CTO, evolved his mission into a business in 2015. The company is gearing up for its next evolution — starting with its first international expansion.

“We’re pivoting away from being a 3D printing company toward a company that personalizes surgery,” Fotheringham tells InnovationMap.

Insight Surgery's focus now is to provide digital planning for surgeons and create personalized medical devices. All the technology the company is working with is FDA approved, but will be customized for patients and surgeons. Previously, this type of customized care could take weeks or months, Fotheringham says, but with Insight Surgery's technology, they can accomplish this in a matter of days.

“We’ve coupled this all together at the point of care by putting people and technology in the hospitals,” Fotheringham explains. “We are changing the norm about (traditional surgery)."

Fotheringham and his team connected with Texas Medical Center Innovation Hub by way of a biobridge — an initiative by TMC to work with international entities to provide an exchange of tech and innovative care. TMC originally launched this UK partnership in 2018 and has expanded it to other countries, including Ireland, Australia, and Denmark.

Insight Surgery is currently building out its 5,000-square-foot space in TMCi that will have a print room for manufacturing. Local operations will be led by David Collins, US engineering lead, who will collaborate with Houston medical professionals at the point of care.

"The US is about 45 percent of the global market for personalized devices, so for us it's part of our expansion — both revenue and investment. We're moving into our fourth round of investment, and the funds will be used for geographic expansion," Fotheringham says. "It's the right time. There's not a lot of competitors."

These three health tech startups are moving on in TMCi's accelerator program. Photo courtesy of TMC

TMC names 3 startups to Houston health tech accelerator

onboarding tech

Thee Texas Medical Center named three companies to its accelerator program. The health tech startups will join the program and make key connections to grow their technology and business.

Texas Medical Center Innovation announced this year's cohort for the TMC Innovation Accelerator for HealthTech. The companies attended TMCi's boot camp earlier this year before being named to the cohort.

“It is always exciting to introduce a new group of talented entrepreneurs into our community,” says Tom Luby, director of TMC Innovation, in a news release. “Each with their own goals, and at their individual stage, we’ll work closely together to help them learn, grow and navigate this rich clinical landscape. We are honored to be the bridge between these innovators and the world’s largest medical city.”

The selected startups include Oxford, United Kingdom-based CardMedic, which joins the program by way of TMC's UK BioBridge, an international partnership established to bring cutting-edge health tech startups to the United States by way of Houston. The company's technology is a digital "One Stop Communication Shop" — an extensive library of pre-written scripts that help staff and patients communicate across any barrier, including language, deafness, cognitive impairment, or disability.

“The opportunity to connect with Texas Medical Center member institutions, understand their problem domain, and in what ways that may differ from the United Kingdom is invaluable. We are really excited about learning from the expert team of strategic advisors at the TMCi Accelerator about areas we needed to focus on to grow our company in the United States,” says Rachael Grimaldi, co-founder and CEO of CardMedic.

Chicago-based CareAdvisors, which helps hospitals and clinical social workers connect patients to the best resources and benefits to address social care needs, also joins the TMCi accelerator. The company's technology, the Social Care Automation tool, enables hospitals to generate revenue from preventive health programs and helps health plans reduce overutilization by putting the focus on preventive care.

Roboligent, based in Austin, designs and manufactures robotic and automated physical therapy exercises for patients with upper and lowers limb musculoskeletal issues. This robotic-assisted rehab help promotes recovery while increasing rehab centers’ operational efficiency.

“Introducing a new and innovative product, especially in the medical device field, is a thorough and collaborative effort,” says Bongsu Kim, founder and CEO of Roboligent, in a news release. “TMC’s HealthTech Accelerator is the perfect place to make connections with experts and stakeholders to help guide us in reaching our next milestone.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice University partners with astronaut foundation to offer new STEM scholarship

space scholars

Rice University has partnered with The Astronaut Scholarship Foundation (ASF) to offer a new scholarship opportunity for junior or senior STEM majors, beginning this spring.

The prestigious Astronaut Scholarship includes up to $15,000, mentorship, networking and a paid trip to the ASF Innovators Symposium and Gala. The scholarship is funded by the James A. Lovell Jr. Family Endowment, in honor of the late American astronaut and founder of the ASF.

“This scholarship opportunity represents an exciting new avenue for Rice STEM students to synthesize their experiences in courses and research and their commitment to advancing the public good as leaders in their field,” Danika Brown, executive director for the Center for Civic Leadership at Rice, said in a news release. “We are so grateful to the Lovell family and to the foundation for investing in Rice students, and we are confident that the foundation will be impressed with our nominees and that selected students will have a life-changing experience as astronaut scholars.”

The Rice Space Institute and the Center for Civic Learning recently hosted the ASF at the Ralph S. O’Connor Building for Engineering and Science.

At the ASF event, Jeff Lovell—son of James Lovell, who commanded Apollo 13 and flew on Apollo 8—announced the scholarship aimed at Rice STEM students. Charlie Duke, who served as spacecraft communicator for the Apollo 11 Moon landing and as the lunar module pilot for Apollo 16, also spoke at the event.

The ASF awarded 74 scholarships to students from 51 universities across the U.S. last May.

The ASF awarded its first seven $1,000 scholarships in 1986 to pay tribute to the Mercury 7 astronauts. It has since awarded more than $10 million to more than 850 college students.

So far, only students from Texas A&M University and the University of Texas at Austin have received the scholarship in Texas.

Houston hospital first in U.S. to use new system for minimally invasive surgery

sharper images

Houston’s Baylor St. Luke’s Medical Center has introduced an innovative new surgical imaging system that will allow surgeons to increase the number of minimally invasive procedures as well as reposition on the fly during operations.

Minimally invasive surgery has been shown across the board to improve patient outcomes with less chance of infection and shorter recovery times compared to traditional open surgery. However, the human body is not exactly easy to work on through small incisions, necessitating the development of state-of-the-art cameras and imaging technology to guide surgeons.

Enter GE HealthCare’s Allia Moveo, now a part of the Baylor St. Luke’s Medical Center operating room. Using cutting-edge technology, it uses the same high-definition imaging usually seen in the catheterization lab at speeds fast enough to respond to shifting surgical conditions. Its cable-free setup allows surgeons to switch positions much faster, and it features advanced 3D imaging that compensates for breathing motion and interference from metal implants.

Its design supports a range of cardiovascular, vascular, non-vascular, interventional and surgical procedures, according to CommonSpirit Health, a nonprofit Catholic health network, of which Baylor St. Luke's is a member.

“This innovative platform enhances how our clinicians navigate complex minimally invasive procedures by improving mobility, image clarity, and workflow efficiency. It strengthens our ability to deliver precise, patient-centered care while supporting our teams with technology designed for the evolving demands of modern interventional medicine,” Dr. Brad Lembcke, president of Baylor St. Luke’s Medical Center, said in a news release from Baylor and the Texas Heart Institute.

Baylor St. Luke’s is the first hospital in the U.S. to use the Allia Moveo technology. The definition and responsiveness of the new system allow surgeons to navigate the body with greater accuracy and smaller incisions, even for very delicate operations.

“Allia Moveo gives us the flexibility and image quality needed to manage increasingly complex minimally invasive procedures with greater confidence,” Dr. Gustavo Oderich, vascular surgeon and professor of surgery at Baylor College of Medicine, added in the release. “The ability to quickly reposition the system, obtain high-quality 3D imaging, and integrate advanced guidance tools directly into the workflow enhances procedural accuracy. This technology supports our mission to push the boundaries of what is possible in endovascular and interventional surgery.”

Houston clocks in as one of the hardest working cities in America

Ranking It

Houston and its residents are proving their tenacity as some of the hardest working Americans in 2026, so says a new study.

WalletHub's annual "Hardest-Working Cities in America (2026)" report ranked Houston the 37th most hardworking city nationwide. H-town last appeared as the 28th most industrious American city in 2025, but it still remains among the top 50.

The personal finance website evaluated 116 U.S. cities based on 11 key indicators across "direct" and "indirect" work factors, such as an individual's average workweek hours, average commute times, employment rates, and more.

The U.S. cities that comprised the top five include Cheyenne, Wyoming (No. 1); Anchorage, Alaska (No. 2); Washington, D.C. (No. 2); Sioux Falls, South Dakota (No. 4); and Irving, Texas (No. 5). Dallas and Austin also earned a spot among the top 10, landing as No. 7 and No. 10, respectively.

Based on the report's findings, Houston has the No. 31-best "direct work factors" ranking in the nation, which analyzed residents' average workweek hours, employment rates, the share of households where no adults work, the share of workers leaving vacation time unused, the share of "engaged" workers, and the rate of "idle youth" (residents aged 16-24 that are not in school nor have a job).

However, Houston lagged behind in the "indirect work factors" ranking, landing at No. 77 out of all 116 cities in the report. "Indirect" work factors that were considered include residents' average commute times, the share of workers with multiple jobs, the share of residents who participate in local groups or organizations, annual volunteer hours, and residents' average leisure time spent per day.

Based on data from The Organisation for Economic Co-operation and Development (OECD), WalletHub said the average American employee works hundreds of more hours than workers residing in "several other industrialized nations."

"The typical American puts in 1,796 hours per year – 179 more than in Japan, 284 more than in the U.K., and 465 more than in Germany," the report's author wrote. "In recent years, the rise of remote work has, in some cases, extended work hours even further."

WalletHub also tracked the nation's lowest and highest employment rates based on the largest city in each state from 2009 to 2024.

ranking

Source: WalletHub

Other Texas cities that earned spots on the list include Fort Worth (No. 13), Corpus Christi (No. 14), Arlington (No. 15), Plano (No. 17), Laredo (No. 22), Garland (No. 24), El Paso (No. 43), Lubbock (No. 46), and San Antonio (No. 61).

Data for this study was sourced from the U.S. Census Bureau, Bureau of Labor Statistics, U.S. Travel Association, Gallup, Social Science Research Council, and the Corporation for National & Community Service as of January 29, 2026.

---

This article originally appeared on CultureMap.com.

View All Listings